Pulmonary embolism and COVID-19 in Europe: epidemiological shifts, inequities, and lessons for the future

Pulmonary embolism (PE) remains a major public health burden, with substantial morbidity, mortality, and healthcare costs.1 The COVID-19 pandemic has added a new dimension to its epidemiology: SARS-CoV-2 infection is associated with heightened thrombotic risk and pandemic-related disruptions to healthcare delivery may have altered patterns of PE diagnosis and management.2,3 However, until now, detailed population-based, monthly trend analyses spanning before, during, and after the pandemic have been lacking.